Literature DB >> 8072198

Tumor doubling time and prognosis in lung cancer patients: evaluation from chest films and clinical follow-up study. Japanese Lung Cancer Screening Research Group.

T Arai1, T Kuroishi, Y Saito, Y Kurita, T Naruke, M Kaneko.   

Abstract

A study was made of the relation between tumor doubling time and prognosis in lung cancer patients. Tumor doubling time was calculated in 237 patients from two serial chest x-ray films. The mean doubling time was 166.3 days, with 221.6 days for adenocarcinoma, 115.2 days for squamous cell carcinoma, 67.5 days for large cell carcinoma, 86.3 days for small cell carcinoma and 225.2 days for others. The patients were divided into three groups in a log-normal distribution of tumor doubling times 109.6 and 252.4 days. The patients with a doubling time of less than 109.6 days were classified as 'rapid growing', those with a doubling time of more than 252.4 days as 'slow growing' and those with a doubling time in between as 'intermediate growing'. The five-year survival rates were 23.3% for 81 'rapid growing' patients, 36.7% for 81 'intermediate growing' patients and 43.3% for 75 'slow growing' patients, with statistically significant differences between groups 'rapid growing' and 'intermediate growing' of P < 0.05 and between groups 'rapid growing' and 'slow growing' of P < 0.01. The five-year survival curves for those who underwent curable resections were 42.4% for 36 rapid growing patients, 53.7% for 31 'intermediate growing' patients and 70.1% for 43 'slow growing' patients. The difference between rapidly growing and slowly growing tumors was statistically significant (P < 0.05). Patients with the more rapidly growing tumors showed a tendency to have a poorer prognosis. It was confirmed that the doubling time of a tumor is an independent factor in the prognosis of lung cancer patients.

Entities:  

Mesh:

Year:  1994        PMID: 8072198

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  33 in total

1.  Microtubule-disrupting chemotherapeutics result in enhanced proteasome-mediated degradation and disappearance of tubulin in neural cells.

Authors:  Lyn M Huff; Dan L Sackett; Marianne S Poruchynsky; Tito Fojo
Journal:  Cancer Res       Date:  2010-06-29       Impact factor: 12.701

2.  Estimation of Solid Tumor Doubling Times from Progression-Free Survival Plots Using a Novel Statistical Approach.

Authors:  Katherine Kay; Keith Dolcy; Robert Bies; Dhaval K Shah
Journal:  AAPS J       Date:  2019-02-08       Impact factor: 4.009

3.  Comparing the benefits of screening for breast cancer and lung cancer using a novel natural history model.

Authors:  Ray S Lin; Sylvia K Plevritis
Journal:  Cancer Causes Control       Date:  2011-11-25       Impact factor: 2.506

4.  Ratio of maximum standardized uptake value to primary tumor size is a prognostic factor in patients with advanced non-small cell lung cancer.

Authors:  Fangfang Chen; Yanwen Yao; Chunyan Ma; Xingqun Ma; Zhaofeng Wang; Tangfeng Lv; Xinwu Xiao; Jie Yin; Yong Song
Journal:  Transl Lung Cancer Res       Date:  2015-02

5.  Association of Uveal Melanoma Metastatic Rate With Stochastic Mutation Rate and Type of Mutation.

Authors:  Eszter Szalai; Yi Jiang; Natasha M van Poppelen; Martine J Jager; Annelies de Klein; Emine Kilic; Hans E Grossniklaus
Journal:  JAMA Ophthalmol       Date:  2018-10-01       Impact factor: 7.389

6.  Population genetics of cancer cell clones: possible implications of cancer stem cells.

Authors:  Christopher T Naugler
Journal:  Theor Biol Med Model       Date:  2010-11-09       Impact factor: 2.432

7.  The proangiogenic phenotype of natural killer cells in patients with non-small cell lung cancer.

Authors:  Antonino Bruno; Chiara Focaccetti; Arianna Pagani; Andrea S Imperatori; Marco Spagnoletti; Nicola Rotolo; Anna Rita Cantelmo; Francesca Franzi; Carlo Capella; Guido Ferlazzo; Lorenzo Mortara; Adriana Albini; Douglas M Noonan
Journal:  Neoplasia       Date:  2013-02       Impact factor: 5.715

8.  Fractionated external beam radiotherapy of skull base metastases with cranial nerve involvement.

Authors:  L H Dröge; T Hinsche; M Canis; B Alt-Epping; C F Hess; H A Wolff
Journal:  Strahlenther Onkol       Date:  2013-12-22       Impact factor: 3.621

9.  Dual strands of the miR-145 duplex (miR-145-5p and miR-145-3p) regulate oncogenes in lung adenocarcinoma pathogenesis.

Authors:  Shunsuke Misono; Naohiko Seki; Keiko Mizuno; Yasutaka Yamada; Akifumi Uchida; Takayuki Arai; Tomohiro Kumamoto; Hiroki Sanada; Takayuki Suetsugu; Hiromasa Inoue
Journal:  J Hum Genet       Date:  2018-08-06       Impact factor: 3.172

10.  Utilization of a hybrid finite-element based registration method to quantify heterogeneous tumor response for adaptive treatment for lung cancer patients.

Authors:  Hoda Sharifi; Hong Zhang; Hassan Bagher-Ebadian; Wei Lu; Munther I Ajlouni; Jian-Yue Jin; Feng-Ming Spring Kong; Indrin J Chetty; Hualiang Zhong
Journal:  Phys Med Biol       Date:  2018-03-21       Impact factor: 3.609

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.